BlackRock
PYXS icon

BlackRock’s Pyxis Oncology PYXS Stock Holding History

BlackRock’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Buy
867,934
+79,095
+10% +$151K ﹤0.01% 4093
2026
Q1 		$1.15M Buy
788,839
+4,762
+0.6% +$7.18K ﹤0.01% 4291
2025
Q4 		$902K Buy
784,077
+100,375
+15% +$354K ﹤0.01% 4332
2025
Q3 		$1.52M Sell
683,702
-243,103
-26% -$350K ﹤0.01% 4179
2025
Q2 		$1.02M Sell
926,805
-2,345,169
-72% -$2.64M ﹤0.01% 4246
2025
Q1 		$3.21M Sell
3,271,974
-72,167
-2% -$96.3K ﹤0.01% 3820
2024
Q4 		$5.22M Buy
3,344,141
+379,981
+13% +$1.1M ﹤0.01% 3709
2024
Q3 		$10.9M Buy
2,964,160
+178,265
+6% +$624K ﹤0.01% 3358
2024
Q2 		$9.22M Buy
2,785,895
+2,464,230
+766% +$10.4M ﹤0.01% 3428
2024
Q1 		$1.37M Buy
321,665
+11,067
+4% +$46.5K ﹤0.01% 4113
2023
Q4 		$559K Buy
310,598
+9,084
+3% +$15.6K ﹤0.01% 4397
2023
Q3 		$600K Buy
301,514
+33,077
+12% +$76.6K ﹤0.01% 4374
2023
Q2 		$687K Buy
268,437
+56,149
+26% +$178K ﹤0.01% 4395
2023
Q1 		$851K Buy
212,288
+956
+0.5% +$1.91K ﹤0.01% 4379
2022
Q4 		$283K Buy
211,332
+4,778
+2% +$7.17K ﹤0.01% 4754
2022
Q3 		$406K Buy
206,554
+1,250
+0.6% +$3.27K ﹤0.01% 4788
2022
Q2 		$489K Sell
205,304
-315,597
-61% -$840K ﹤0.01% 4778
2022
Q1 		$2.1M Buy
520,901
+7,053
+1% +$51.6K ﹤0.01% 4367
2021
Q4 		$5.64M Buy
+513,848
New +$5.88M ﹤0.01% 3944

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BlackRock's PYXS Position: Q2 2026 in Review

BlackRock increased its Pyxis Oncology (PYXS) stake by 10% in Q2 2026, buying an estimated $151K and bringing the position to 867,934 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #4093.

BlackRock first reported a position in PYXS in Q4 2021 and has held it in 19 quarters since. The position peaked at $10.9M in Q3 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • BlackRock held 867,934 shares of Pyxis Oncology worth $2.61M as of Q2 2026.
  • BlackRock bought 79,095 Pyxis Oncology shares in Q2 2026, an estimated $151K.
  • Pyxis Oncology made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4093 holding.
  • BlackRock first reported a position in Pyxis Oncology in Q4 2021 and has held it in 19 quarters since.
  • BlackRock's Pyxis Oncology position peaked at $10.9M in Q3 2024.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.